Refine Results
- view as grid
- view as list
Expanding Medicare to Adults at Age 60 Years—Medicare-for-More?
In this column for the JAMA Health Forum, Larry Levitt examines the implications of lowering Medicare’s age of eligibility, which is emerging as a potential pathway toward Medicare-for-all or a public option among single-payer advocates. He explores the implications for costs, industry, people and broader reform efforts.
Perspective Read More
Persistent Vaccine Myths
With news that the country has now vaccinated half of its population with at least one dose, This Drew Altman Axios column highlights the persistent COVID-19 vaccine myths that are believed by a substantial portion of the unvaccinated population and discusses the options to address vaccine misinformation.
Perspective Read More
We aren’t getting a national vaccine ‘passport.’ So let’s use the next best thing: CDC vaccination cards.
In this op-ed for The Washington Post, Drew Altman suggests a way out of the heated debate about a COVID-19 vaccination passport to help provide clarity about who is vaccinated and who still ought to wear masks in public spaces or the workplace by using something that already exists– CDC vaccination cards.
Perspective Read More
Corporate Leaders Are Getting Bullish On Government Action On Health Care Costs
In this Axios column, Drew Altman explores whether the long struggle with rising health costs has caused the tide to turn in corporate leaders’ attitudes towards government involvement in controlling health spending and whether it is part of a larger shift in comfort with government action to solve problems.
Perspective Read More
Why Doctors and Nurses Can Be Vital Vaccine Messengers
In this Axios column, Drew Altman examines why doctors and nurses are such critical messengers in the effort to build vaccine confidence.
Perspective Read More
Dysfunctional websites are making it harder for Americans to get vaccinated. Here’s how to fix that.
In an op-ed for The Washington Post, Drew Altman spells out how COVID-19 vaccination can be simplified to ensure that the public’s rising confidence in the vaccine isn’t thwarted by frustrating and sometimes dysfunctional websites.
Perspective Read More
Where To Start To Build Vaccine Confidence
In this Axios column Drew Altman writes about the recent attention to Republican vaccine resisters. “Republicans and rural Americans are among the most resistant vaccine holdouts and some strategies are emerging to reach them.” But “far from all Republicans are resisters” and “the bigger and quicker payoff will come from prioritizing the more moveable group of ‘wait and see’ Americans.”
Perspective Read More
Vaccine Confidence Isn’t The Main Obstacle To Reaching Herd Immunity
In this Axios column, Drew Altman paints a more optimistic picture of the prospects for getting to herd immunity as vaccine confidence grows, but underscores the urgency of building vaccine confidence in Black and Latino communities where barriers to access and good information are obstacles to getting vaccinated.
Perspective Read More
Insurance coverage and financing landscape for HIV treatment and prevention in the USA
In this article for The Lancet, KFF’s Jennifer Kates and Lindsey Dawson, and five co-authors provide an overview of the coverage and financing landscape for HIV treatment and prevention in the U.S., discuss how the Affordable Care Act has changed the domestic health care system, examine the major programs that…
Perspective Read More
Seeing Others Vaccinated May Be The Best Cure For Vaccine Hesitancy
In his latest Axios column, Drew Altman shows why vaccine hesitancy will naturally decrease as more and more people see their family members and friends vaccinated without adverse consequences. It’s a hopeful sign about vaccine hesitancy, and should help free up resources to focus on the remaining vaccine hesitant.
Perspective Read More